

INDEPENDENT AUDITOR'S REPORT

To the Members of Suraksha Diagnostic Private Limited

Report on the Audit of the Standalone Financial Statements

Opinion

We have audited the standalone financial statements of **Suraksha Diagnostic Private Limited** ("the Company"), which comprise the Balance Sheet as at March 31, 2022, and the Statement of Profit and Loss and Statement of Cash Flows for the year then ended, and notes to the standalone financial statements, including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the Accounting Standards prescribed under section 133 of the Act read with Companies (Accounts) Rules, 2014 as amended and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2022, and profit and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the standalone financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Information Other than the Standalone Financial Statements and Auditor's Report Thereon

The Company's Board of Directors is responsible for the other information. The other information comprises the Director's report but does not include the standalone financial statements and our auditor's report thereon. The Director's Report is expected to be made available to us after the date of this auditor's report.

Our opinion on the standalone financial statements does not cover the other information and we will not express any form of assurance conclusion thereon.

In connection with our audit of the standalone financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statement or our knowledge obtained in the audit or otherwise appears to be materially misstated.



MSKA & Associates

Chartered Accountants

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. As described below, we have concluded that such a material misstatement of the other information exists.

Responsibilities of Management for Standalone Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate of accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial statements, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Statements

Our objectives are to obtain reasonable assurance about whether the standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial statements.

We give in "Annexure A" a detailed description of Auditor's responsibilities for Audit of the Standalone Financial Statements.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in "Annexure B" a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.



2. As required by Section 143(3) of the Act, we report that:
- a. We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - b. In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
 - c. The Balance Sheet, the Statement of Profit and Loss and the Statement of Cash Flow dealt with by this Report are in agreement with the books of account.
 - d. In our opinion, the aforesaid standalone financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
 - e. On the basis of the written representations received from the directors as on March 31, 2022 taken on record by the Board of Directors, none of the directors are disqualified as on March 31, 2022 from being appointed as a director in terms of Section 164 (2) of the Act.
 - f. With respect to the adequacy of the internal financial controls with reference to standalone financial statements of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure C".
 - g. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company has disclosed the impact of pending litigations on its financial position in its standalone financial statements - Refer Note 33 to the standalone financial statements;
 - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
 - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.
 - iv. 1. The Management has represented that, to the best of its knowledge and belief, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.



MSKA & Associates

Chartered Accountants

2. The Management has represented, that, to the best of it's knowledge and belief, no funds have been received by the Company from any person(s) or entity(ies), including foreign entities (Funding Parties), with the understanding, whether recorded in writing or otherwise, as on the date of this audit report, that the Company shall, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
 3. Based on the audit procedures performed that have been considered reasonable and appropriate in the circumstances, and according to the information and explanations provided to us by the Management in this regard nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e) as provided under (1) and (2) above, contain any material mis-statement.
 - v. The Company has neither declared nor paid any dividend during the year.
3. In our opinion, according to information, explanations given to us, the provisions of Section 197 of the Act and the rules thereunder are not applicable to the Company as it is a private Company.

For M S K A & Associates
Chartered Accountants
ICAI Firm Registration No. 105047W


Puneet Agarwal
Partner
Membership No. 064824
UDIN: 22064824AXNQXD9944



Place: Kolkata
Date: 30/09/2022

**ANNEXURE A TO THE INDEPENDENT AUDITOR'S REPORT ON EVEN DATE ON THE
STANDALONE FINANCIAL STATEMENTS OF SURAKSHA DIAGNOSTIC PRIVATE LIMITED**

Auditor's Responsibilities for the Audit of the Standalone Financial Statements

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has internal financial controls with reference to standalone financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.



MSKA & Associates

Chartered Accountants

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

For M S K A & Associates
Chartered Accountants
ICAI Firm Registration No. 105047W




Puneet Agarwal
Partner

Membership No. 064824
UDIN: 22064824AXNQXD9944

Place: Kolkata
Date: 30/09/2022

ANNEXURE B TO INDEPENDENT AUDITORS' REPORT OF EVEN DATE ON THE STANDALONE FINANCIAL STATEMENTS OF SURAKSHA DIAGNOSTIC PRIVATE LIMITED FOR THE YEAR ENDED MARCH 31, 2022.

[Referred to in paragraph 1 under 'Report on Other Legal and Regulatory Requirements' in the Independent Auditors' Report]

i.

- (a) A. The Company has not maintained proper records showing full particulars including quantitative details and situation of Property, Plant and Equipment. The details of the same are as below:

Description of Property, Plant and Equipment	Amount (Rs. In lac)
Plant & Machinery	Rs 439.92
Computer Hardware	Rs 105.83
Furniture and fixtures	Rs 2,365.41
Laboratory Equipment	Rs 7,537.13
Vehicles	Rs 187.20
Computer Server	Rs 3.09
Office Equipment	Rs 100.71

B. The Company has maintained proper records showing full particulars of intangible assets.

- (b) All the Property, Plant and Equipment were physically verified by the management in the previous year in accordance with a planned programme of verifying them once in three years which, in our opinion, is reasonable having regard to the size of the Company and the nature of its assets. No material discrepancies were noticed on such verification.
- (c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the title deeds of immovable properties as disclosed in the standalone financial statements are held in the name of the Company.
- (d) According to the information and explanations given to us, the Company has not revalued its property, plant and equipment or intangible assets or both during the year. Accordingly, the requirements under paragraph 3(i)(d) of the Order are not applicable to the Company.
- (e) According to the information and explanations given to us, no proceeding has been initiated or pending against the Company for holding benami property under the Benami Transactions (Prohibition) Act, 1988 and rules made thereunder. Accordingly, the provisions stated in paragraph 3(i) (e) of the Order are not applicable to the Company.



- ii.
- (a) The inventory has been physically verified during the year by the management. In our opinion, the frequency of verification, coverage & procedure of such verification is reasonable and appropriate. No material discrepancies were noticed on such verification.
- (b) The Company has not been sanctioned any working capital limits during the year. Accordingly, the requirements under paragraph 3(ii)(b) of the Order is not applicable to the Company.
- iii. According to the information explanation provided to us, the Company has made investments and provided guarantee or security on behalf of parties during the year. The Company has not provided any loans or advances in the nature of loans, secured or unsecured, to companies, firms, Limited Liability Partnerships or any other parties. Hence, the requirements under paragraph 3(iii) (c) to (f) of the Order are not applicable to the Company.
- (a)
- A. According to the information and explanations given to us, the Company has not provided any guarantee or given any security to subsidiaries during the year. The Company does not have any joint venture or associates.
- B. The details of such guarantee provided and security given on behalf of parties other than subsidiary are as follows:

Particulars	Guarantee & Security (Amount in Rs. Lacs)
Aggregate amount provided during the year	Rs 2,842.22
- Others	
Balance Outstanding as at balance sheet date in respect of above case	Rs. 2,842.22
- Others	

- (b) According to the information and explanations given to us and based on the audit procedures performed by us, we are of the opinion that the terms and conditions in relation to investments made are not prejudicial to the interest of the Company. In the absence of terms and conditions in relation to guarantee provided and security given, we are unable to comment on whether the guarantee or security given are prejudicial to the interest of the Company.
- iv. According to the information and explanations given to us, the Company has complied with the provisions of section 185 and 186 of the Act, in respect of loans, investments, guarantees and securities made.



According to the information and explanations given to us, the Company has not accepted any deposits from the public within the meaning of Sections 73, 74, 75 and 76 of the Act and the rules framed there under.

vi. We have broadly reviewed the books of account maintained by the Company pursuant Rules made by the Central Government for the maintenance of cost records under section 148 of the Act and we are of the opinion that prima facie the prescribed accounts and records have been made and maintained. We have not, however, made a detailed examination of the records with a view to determine whether they are accurate or complete

vii.

(a) According to the information and explanations given to us and the records of the Company examined by us, in our opinion, undisputed statutory dues including goods and service tax, provident fund, employees' state insurance, income-tax, and any other statutory dues have not generally been regularly deposited by the Company with the appropriate authorities though delay in deposit have not been serious. There was no liability towards excise duty, custom duty and cess during the year and hence not commented upon.

There are no disputed amounts payable in respect of provident fund, employee's state insurance, income tax, goods and service tax and other statutory dues in arrears as at March 31, 2022 for a period of six months from the date they become payable.

(b) According to the information and explanation given to us and the records of the Company examined by us, there are no dues of income tax, goods and service tax, customs duty, cess and any other statutory dues which have not been deposited on account of any dispute.

viii. According to the information and explanations given to us, there are no transactions which are not accounted in the books of account which have been surrendered or disclosed as income during the year in Tax Assessment of the Company. Also, there are no previously unrecorded income which has been now recorded in the books of account. Hence, the provision stated in paragraph 3(viii) of the Order is not applicable to the Company.

ix.

(a) In our opinion and according to the information and explanations given to us, the Company has not defaulted in repayment of loans or borrowings or in payment of interest thereon to any lender.

(b) According to the information and explanations given to us and on the basis of our audit procedures, we report that the Company has not been declared willful defaulter by any bank or financial institution or government or any government authority.

(c) In our opinion and according to the information explanation provided to us, money raised by way of term loans during the year have been applied for the purpose for which they were raised.

(d) According to the information and explanation provided to us, there are no funds raised on short term basis during the year. Accordingly, the provision stated in paragraph 3(ix)(d) of the Order is not applicable to the Company.



- (e) According to the information explanation given to us and on an overall examination of the standalone financial statements of the Company, we report that the Company has not taken any funds from an any entity or person on account of or to meet the obligations of its subsidiaries.
- (f) According to the information and explanations given to us and procedures performed by us, we report that the Company has not raised loans during the year on the pledge of securities held in its subsidiaries. Hence, reporting under the clause 3(ix)(f) of the order is not applicable to the Company.
- x.
- (a) In our opinion and according to the information explanation given to us, the Company did not raise any money by way of initial public offer or further public offer (including debt instruments) during the year. Hence, the provisions stated in paragraph 3 (x)(a) of the Order are not applicable to the Company.
- (b) According to the information and explanations given to us and based on our examination of the records of the Company, the Company has not made any preferential allotment or private placement of shares or fully, partly or optionally convertible debentures during the year. Hence, the provisions stated in paragraph 3 (x)(b) of the Order are not applicable to the Company.
- xi.
- (a) Based on our examination of the books and records of the Company, carried out in accordance with the generally accepted auditing practices in India, and according to the information and explanations given to us, we report that no material fraud by the Company nor on the Company has been noticed or reported during the course of our audit.
- (b) We have not come across of any instance of material fraud by the Company or on the Company during the course of audit of the standalone financial statement for the year ended March 31, 2022, accordingly the provisions stated in paragraph (xi)(b) of the Order is not applicable to the Company.
- (c) As represented to us by the Management, there are no whistle-blower complaints received by the Company during the year.
- xii.
- (a) The Company is not a Nidhi Company. Accordingly, the provisions stated in paragraph 3(xii) (a) to (c) of the Order are not applicable to the Company.
- xiii. According to the information and explanations given to us and based on our examination of the records of the Company, transactions with the related parties are in compliance with section 188 of the Act, where applicable and details of such transactions have been disclosed in the standalone financial statements as required by the applicable accounting standards. Section 177 of the Act is not applicable on the Company and hence not commented upon.



xiv.

(a) In our opinion and based on our examination, the Company does not have an internal audit system and is not required to have an internal audit system as per provisions of the Companies Act.

(b) The Company did not have an internal audit system for the period under audit.

xv. According to the information and explanations given to us, in our opinion during the year the Company has not entered into non-cash transactions with directors or persons connected with its directors and hence, provisions of section 192 of the Act are not applicable to Company.

xvi.

(a) The Company is not required to be registered under section 45 IA of the Reserve Bank of India Act, 1934 and accordingly, the provisions stated in paragraph 3 (xvi)(a) of the Order are not applicable to the Company.

(b) The Company has not conducted any Non-Banking Financial or Housing Finance activities without any valid Certificate of Registration from Reserve Bank of India. Hence, the reporting under paragraph 3 (xvi)(b) of the Order are not applicable to the Company.

(c) The Company is not a Core investment Company (CIC) as defined in the regulations made by Reserve Bank of India. Hence, the reporting under paragraph 3 (xvi)(c) of the Order are not applicable to the Company.

(d) The Group does not have any CIC as part of its group. Hence the provisions stated in paragraph 3 (xvi) (d) of the order are not applicable to the Company.

xvii. Based on the overall review of standalone financial statements, the Company has not incurred cash losses in the current financial year and in the immediately preceding financial year. Hence, the provisions stated in paragraph 3 (xvii) of the Order are not applicable to the Company.

xviii. There has been no resignation of the statutory auditors during the year. Hence, the provisions stated in paragraph 3 (xviii) of the Order are not applicable to the Company.

xix. According to the information and explanations given to us and on the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the standalone financial statements, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report that Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however,



MSKA & Associates

Chartered Accountants

state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.

- xx. According to the information and explanations given to us and based on our verification, the provisions of section 135 of the Act are applicable to the Company. The Company has made the required contributions during the year and there are no unspent amounts which are required to be transferred either to a Fund or to a Special Account as per the provisions of section 135 of the act read with schedule VII. Accordingly, reporting under clause 3(xx)(a) and clause 3(xx)(b) of the Order is not applicable to the Company.
- xxi. The reporting under clause 3(xxi) of the Order is not applicable in respect of audit of standalone financial statements. Accordingly, no comment in respect of the said clause has been included in the report.

For M S K A & Associates
Chartered Accountants
ICAI Firm Registration No: 105047W


Puneet Agarwal
Partner
Membership No.064824
UDIN: 22064824AXNQXD9944



Place: Kolkata
Date: 30/09/2022

ANNEXURE C TO THE INDEPENDENT AUDITOR'S REPORT OF EVEN DATE ON THE STANDALONE FINANCIAL STATEMENTS OF SURAKSHA DIAGNOSTIC PRIVATE LIMITED

[Referred to in paragraph 2(f) under 'Report on Other Legal and Regulatory Requirements' in the Independent Auditors' Report of even date to the Members of Suraksha Diagnostic Private Limited on the Financial Statements for the year ended March 31, 2022

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

Opinion

We have audited the internal financial controls with reference to standalone financial statements of Suraksha Diagnostic Private Limited ("the Company") as of March 31, 2022 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

In our opinion, the Company has, in all material respects, an adequate internal financial controls with reference to standalone financial statements and such internal financial controls with reference to standalone financial statements were operating effectively as at March 31, 2022, based on the internal control with reference to standalone financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India (ICAI) (the "Guidance Note").

Management's Responsibility for Internal Financial Controls

The Company's Management is responsible for establishing and maintaining internal financial controls based on the internal control with reference to standalone financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls with reference to standalone financial statements based on our audit. We conducted our audit in accordance with the Guidance Note and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Act, to the extent applicable to an audit of internal financial controls. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to standalone financial statements was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to standalone financial statements and their operating effectiveness. Our audit of internal financial controls with reference to standalone financial statements included obtaining an understanding of internal financial controls with reference to standalone financial statements, assessing the risk that a material weakness exists, and testing and



evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the standalone financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls with reference to standalone financial statements.

Meaning of Internal Financial Controls With reference to Standalone Financial Statements

A Company's internal financial control with reference to standalone financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of standalone financial statements for external purposes in accordance with generally accepted accounting principles. A Company's internal financial control with reference to standalone financial statements includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of standalone financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the standalone financial statements.

Inherent Limitations of Internal Financial Controls With reference to Standalone financial statements

Because of the inherent limitations of internal financial controls with reference to standalone financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to standalone financial statements to future periods are subject to the risk that the internal financial control with reference to standalone financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

For M S K A & Associates
Chartered Accountants
ICAI Firm Registration No. 105047W


Puneet Agarwal
Partner

Membership No.064824
UDIN: 22064824AXNQXD9944

Place: Kolkata
Date: 30/09/2022

Particulars	Notes	As at 31-Mar-2022	As at 31-Mar-2021
Equity & Liabilities			
Shareholder's Fund			
Share Capital	3	852.86	852.86
Reserves & Surplus	4	14,148.55	11,773.45
Total Shareholder's Fund		15,001.41	12,626.31
Liabilities			
Non - Current Liabilities			
(a) Long-Term Borrowings	5	1,228.13	992.85
(b) Deferred Tax Liability (Net)	6	1,004.71	982.91
(c) Long-Term Provisions	7	31.14	11.01
Total Non-Current Liabilities		2,263.98	1,986.77
Current Liabilities			
(a) Short-Term Borrowings	8	673.81	650.21
(b) Trade Payables			
- Total outstanding dues of micro enterprises and small enterprises	9	4.29	4.63
- Total outstanding dues of creditors other than micro enterprises and small enterprises	9	1,382.98	1,255.69
(c) Other Current Liabilities	10	626.48	583.79
(d) Short-Term Provisions	11	120.60	0.30
Total Current Liabilities		2,808.16	2,494.62
Total Equity & Liabilities		20,073.55	17,107.70
Assets			
Non-Current Assets			
(a) Property, Plant and Equipment	12	11,755.30	11,691.31
(b) Other Intangible Assets	13	175.38	207.93
(c) Capital Work-in-Progress	12	109.31	0.86
(d) Intangible Assets Under Development	13	-	15.05
(e) Non-Current Investments	14	15.50	10.50
(f) Long-Term Loans & Advances	15	197.06	180.00
(g) Other Non-Current Assets	16	5,634.81	2,270.54
Total Non-Current Assets		17,887.36	14,376.19
Current Assets			
(a) Current Investments	17	-	541.18
(b) Inventories	18	622.53	444.50
(c) Trade Receivables	19	756.70	599.53
(d) Cash and Bank Balances			
- Cash and cash equivalents	20	258.02	285.58
- Other bank balances	20	25.00	149.83
(e) Short-Term Loans & Advances	21	523.94	710.89
Total Current Assets		2,186.19	2,731.51
Total Assets		20,073.55	17,107.70
Summary of Significant Accounting Policies	2		


The accompanying notes are an integral part of the standalone financial statements.

As per our report of even date
 For M S K A & Associates
 Chartered Accountants
 (CAI Firm Registration No.:105047W)

 Puneet Agarwal
 Partner
 Membership No. 064824



Suraksha Diagnostic Private Limited
 for and on behalf of the Board of Directors of


 Dr Somnath Chatterjee
 Director
 DIN: 00137075


 Riku Mittal
 Director
 DIN: 00165886

Place: Kolkata
 Date: 30-03-2022



Suraksha Diagnostic Private Limited
CIN:U85110WB2005PTC102265
Statement of Profits and Loss for the year ended March 2022
(all amounts in INR Lacs, unless stated otherwise)

Particulars	Notes	For the year ended 31 March 2022	For the year ended 31 March 2021
Income			
I Revenue from Operations	22	22,319.25	14,000.57
II Other Income	23	230.34	137.60
III Total Income (I + II)		22,549.59	14,138.17
IV Expenses:			
Cost of Materials Consumed	24	6,040.49	2,600.96
Employee Benefits Expenses	25	3,413.94	2,489.48
Finance Costs	26	152.56	156.02
Depreciation and Amortisation Expenses	27	1,509.13	1,571.16
Other Expenses	28	8,114.10	6,679.23
V Total Expenses		19,230.22	13,496.85
VI Profit before Tax (III - V)		3,319.37	641.32
VII Tax Expenses :			
Current Tax (Net of MAT credit utilized amounting to Rs.21.28 lacs (Previous Year Rs.173.19 lacs)		922.47	133.17
Tax Relating to Earlier Years		-	5.46
Deferred Tax	6	21.80	(144.76)
		944.27	(6.13)
VIII Profit After Tax for the Year (VIII - IX)		2,375.10	647.45
Earnings per equity share (Nominal value of Rs 100/-)	29		
- Basic		344	94
- Diluted		278	76

The accompanying notes are an integral part of the standalone financial statements.

As per our report of even date
For M S K A & Associates
Chartered Accountants
ICAI Firm Registration No.: 105047W

Puneet Agarwal
Partner
Membership No. 064824

Place: Kolkata
Date: 30-03-2022

Suraksha Diagnostic Private Limited
for and on behalf of the Board of Directors of


Dr Somnath Chatterjee
Director
DIN: 00137075


Ritu Mittal
Director
DIN: 00165886



Particulars	For the year ended 31 March 2022	For the year ended 31 March 2021
A Cash Flow From Operating Activities		
Profit before Tax	3,319.37	641.32
Adjustment to reconcile profit before tax to net cash flows		
Depreciation and amortisation expense	1,509.13	1,571.16
Interest Income	(181.13)	(59.68)
Loss on Sale of Assets	141.48	245.03
Net gain on sale of current investments	(0.29)	(29.42)
Dividend income from mutual funds	(0.64)	(1.46)
Provision for doubtful debts	-	284.38
Liabilities / Provisions no longer required now Written back	(37.07)	(33.71)
Interest Expenses	152.56	156.01
Operating profit before working capital changes	4,903.41	2,773.63
Movement in working capital:		
(Increase)/Decrease in Inventory	(178.02)	100.12
(Increase)/Decrease in Trade Receivables	(116.26)	(284.39)
(Increase)/Decrease in Loans and Advances & Other Assets	(194.36)	(62.78)
Increase/(Decrease) in Trade Payables	123.10	(33.14)
Increase/(Decrease) in Other Liabilities	100.85	(0.27)
Increase/(Decrease) in Provision	37.98	11.31
Cash generated from operations	4,676.70	2,504.48
Income Tax Payments (including MAT Credit and net of refunds)	443.64	150.33
Net Cash generated from operating activities	4,233.06	2,354.15
B Cash Flows from Investing Activities		
Purchase of property, plant & equipment and intangibles assets including capital work in progress and capital advances	(1,910.68)	(1,540.06)
Payment of purchase consideration against acquisition of property, plant & equipment	-	(335.99)
Proceeds from sale of current investments	34.41	25.00
Investment in Suraksha Speciality LLP	541.47	557.78
Purchase of current investments	(5.00)	(0.50)
Dividend Income from Investments	-	(531.35)
Investment in fixed deposits (having original maturity of more than three months)	0.64	1.46
Interest Received	(3,211.30)	(1,007.35)
Net Cash used in Investing activities	(4,369.33)	(2,771.33)
C Cash flow from Financing Activities		
Increase in Secured Loans	278.78	323.40
(Decrease)/Increase in Unsecured Loans	(19.90)	159.70
Interest Paid	(150.17)	(162.04)
Net Cash generated from Financing activities	108.71	321.06
Net increase/(decrease) in cash and cash equivalent	(A+B+C) (27.56)	(96.13)
Cash and Cash Equivalents at beginning of the year	285.58	381.71
Cash and Cash Equivalents at end of the year	258.02	285.58
Components of Cash and Cash Equivalent		
Cash in hand	30.45	54.89
Balance with Bank on Current Accounts	213.61	212.29
Prepaid Bank Balances	13.96	18.40
	258.02	285.58


Notes

- The above Cash Flow Statement has been prepared under the "Indirect Method" as stated in Accounting Standard 3 in 'Cash Flow Statement' prescribed under Companies Act, 2013
- Negative figures has been shown in bracket
- Previous Period's Figure have been regrouped/rearranged wherever necessary to confirm with current year's presentation

As per our report of even date
 For M S K A & Associates
 Chartered Accountants
 ICAI Firm Registration No.: 105047W

 Puneet Agarwal
 Partner
 Membership No: 064824

For and on behalf of the Board of Directors of
 Suraksha Diagnostic Private Limited


 Dr Somnath Chatterjee
 Director


 Ritu Mittal
 Director

Place: Kolkata
 Date: 30-09-2022



Suraksha Diagnostic Private Limited

Notes forming part of the Standalone Financial Statements as at and for the year ended March 31, 2022

CIN: U85110WB2005PTC102265

1. Company Overview

Suraksha Diagnostic Private Limited is private limited company domiciled in India and incorporated on 15 March 2005 under the provision of Companies Act, 1956. The company is principally engaged in the business of running diagnostic centers for carrying out various pathological and radiological services.

Registered and Corporate office of the Company is located at Plot No. DG-12/1, Action Area 1D Premises No 02-0327, New Town, Rajarhat Kolkata - 700156, West Bengal, India.

2. Basis of Preparation of Standalone Financial Statements:

a) Basis of Preparation

These financial statements have been prepared in accordance with the generally accepted accounting principles in India (Indian GAAP) under historical cost convention on an accrual basis in compliance with all material aspects of the Accounting Standards (AS) notified under section 133 of the Companies Act, 2013 read together with Rule 7 of the Companies (Accounts), Rules 2014 and the Companies (Accounting Standard) Amendment Rules, 2016 and other accounting principles generally accepted in India (referred to as "Indian GAAP"), which have been approved by the Board of Directors at their meetings held on 30th of September 2022.

The accounting policies applied by the Company are consistent with those used in the previous year and the adjustments related to material errors & regrouping/reclassifications has been incorporated for the financial year ended March 31, 2021, to reflect the same accounting treatment as per the accounting policy and grouping/classifications followed as at and for the period ended March 31, 2022. These notes provide a list of the significant accounting policies adopted in the preparation of these Standalone Financial Statements. These policies have been consistently applied to all the years presented, unless otherwise stated.

All assets and liabilities have been classified as current or non-current as per the Company's normal operating cycle and other criteria set out in the schedule III to the Companies Act, 2013. Based on the nature of business and the time between acquisition of assets for processing and their realization in cash and cash equivalents, the company has ascertained its operating cycle as 12 months for the purpose of current or non-current classification of assets and liabilities.

b) Functional and presentation currency

The Standalone Financial Statements are presented in Indian Rupees "INR" or "Rs." unless indicated otherwise.

c) Recent Accounting Developments

MCA issued notifications dated March 24, 2021, to amend Schedule III to the Companies Act, 2013 to enhance the disclosures required to be made by the Company in its financial statements. These amendments are applicable to the Company for the financial period starting April 1, 2021.



3. Summary of Significant Accounting Policies:

a) Revenue recognition

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured.

Revenue from Diagnostic Services comprises of amount billed (net of discounts) in respect of tests conducted and is recognized as and when the samples are collected for the purposes of conducting the tests.

Rental Income and Income from Manpower Supply recognized on an accrual basis based on the agreements/arrangement with the concern parties.

Interest income is recognized on a time proportion basis considering the amount outstanding and the rate applicable.

Dividend income is recognized when the right to receive payment is established, provided it is probable that the economic benefits associated with the dividend will flow to the Company, and the amount of the dividend can be measured reliably.

b) Property, plant & equipment - tangible assets

- i. The initial cost of Property, plant & equipment comprises its purchase price, including import duties and non-refundable purchase taxes, attributable borrowing cost, and any other cost directly attributable to bringing the asset to its working condition and location for its intended use and net charges on foreign exchange contracts and adjustments arising from exchange rate variations attributable to the assets.

Subsequent expenditure relating to tangible assets is capitalized only if such expenditure results in an increase in the future benefits from such asset beyond its previously assessed standard of performance.

- ii. Expenditure incurred after the property, plant and equipment have been put into operation, such as repairs and maintenance, are normally charged to Profit and Loss a/c for the year in which the costs are incurred.
- iii. Gains and losses on disposal of an item of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of property, plant and equipment, and are recognized net within other income/other expenses in the statement of Profit and Loss a/c.
- iv. The residual values, useful lives, and methods of depreciation of property, plant and equipment are reviewed at the end of each year/period and adjusted prospectively, if appropriate.

c) Capital work in progress

Assets during construction are capitalized in capital work in progress account. At the point when an asset can operate in the manner intended by management, the cost of construction is transferred to the appropriate category of property, plant and equipment. Costs associated with the commissioning of an asset are capitalized when the asset is available for use but incapable of operating at normal levels until the period of commissioning has been completed. Capital work in progress is stated at cost, net of accumulated impairment loss, if any.



d) Depreciation on property, plant & equipment

Assets during development or construction and freehold land are not depreciated. These assets are tested for impairment.

Other property, plant and equipment are stated at cost less accumulated depreciation and accumulated impairment loss, if any. Depreciation commences when the assets are ready for their intended use.

Based on management's evaluation, useful life prescribed in Schedule II of the Companies Act, 2013 represent actual useful life of property, plant and equipment. The Company uses Straight Line to provide depreciation on different class of its property, plant and equipment.

Depreciation on addition to tangible assets is provided on pro-rata basis from the date the assets are ready for intended use. Depreciation on sale/discard from tangible assets is provided for upto the date of sale, deduction or discard of tangible assets, as the case may be.

e) Intangible assets

Intangible assets acquired separately are measured on initial recognition at cost. The cost comprises purchase price, borrowing costs, and any cost directly attributable to bringing the asset to its working condition for the intended use and net charges on foreign exchange contracts and adjustments arising from exchange rate variations attributable to the intangible assets. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and accumulated impairment losses (if any).

An intangible asset is derecognized upon disposal (i.e., at the date the recipient obtains control) or when no future economic benefits are expected from its use or disposal. Any gain or loss arising upon derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the statement of Profit and Loss a/c when the asset is derecognized.

Amortization of intangible assets has been calculated on straight line basis at the following rates, based on management estimates, which in the opinion of the management are reflective of the estimated useful lives of the Intangible assets.

Particulars	Useful life (In years)
Computer Software	5 to 10 years

Amortization on addition to intangible assets is provided on pro-rata basis from the date the assets are ready for intended use. The amortization expense on intangible assets is recognized in the statement of Profit and Loss a/c unless such expenditure forms part of carrying value of another asset.

f) Borrowing Costs

Borrowing cost includes interest, amortization of ancillary costs incurred in connection with the arrangement of borrowings and exchange differences arising from foreign currency borrowings to the extent they are regarded as an adjustment to the interest cost.

Borrowing costs that are directly attributable to the acquisition, construction or production of an asset that takes a substantial period to get ready for its intended use are capitalized. All other borrowing costs are recognized as expenditure in the period in which they are incurred.



g) Investments

Investments, which are readily realizable and intended to be held for not more than one year from the date on which such investments are made, are classified as current investments. All other investments are classified as long-term investments.

On initial recognition, all investments are measured at cost. The cost comprises purchase price and directly attributable acquisition charges such as brokerage, fees and duties.

Current investments are carried in the financial statements at lower of cost and fair value determined on an individual investment basis. Long-term investments are carried at cost.

On disposal of an investment, the difference between its carrying amount and net disposal proceeds is charged or credited to the statement of Profit and Loss a/c.

h) Foreign Currency transaction

Initial recognition:

Foreign currency transactions are recorded in the reporting currency by applying the exchange rate between the reporting currency and the foreign currency at the date of the transaction.

Conversion:

Foreign currency monetary items are reported using the closing rate. Non-monetary items which are carried in terms of historical cost denominated in a foreign currency are reported using the exchange rate at the date of the transaction; non-monetary items which are carried at fair value or other similar valuation denominated in a foreign currency are reported using the exchange rates that existed when such values were determined.

Exchange differences:

Exchange differences arising on the settlement of monetary items or on reporting the Company's monetary items at rates different from those at which they were initially recorded during the year, or reported in previous financial statements, are recognized as income or as expenses in the year in which they occur.

i) Inventories:

Inventories comprises of reagents, chemicals, surgical and laboratory supplies, and others are valued at lower of cost and net realizable value.

Cost is determined on First in First out (FIFO) method. The cost of Inventory comprise all costs of purchase and other costs incurred in bringing the inventories to their present location and condition.

j) Retirement and other Employee Benefits:

- i. Employee benefits payable wholly within twelve months of receiving employee services are classified as short-term employee benefits. These benefits include salaries, dearness allowance, leave encashment, house rent allowance, ex-gratia and various other allowance.
- ii. The Company makes defined contribution to Government Employee Provident Fund, Government Employee Pension Fund, ESI, which are recognized in the Statement of Profit and Loss on accrual basis. Such benefits are classified as Defined Contribution Schemes as the Company does not have any further obligations under these plans beyond its monthly contributions.



- iii. The Company's gratuity benefit scheme is a defined benefit plan. The calculation of the Company's obligation under the plan is performed annually by a qualified actuary using the projected unit credit method. Actuarial gains and losses are recognized in the Statement of Profit and Loss in the year in which they arise.

The Company has taken up a Group Gratuity Scheme with Life Insurance Corporation of India (LIC), 'Suraksha Diagnostic Private Limited Employees' Gratuity Fund' to meet its obligation towards gratuity. The contributions made to the Fund are recognized as plan assets. The gratuity benefit obligation recognized in the balance sheet represents the present value of the defined benefit obligation as reduced by the fair value of plan assets.

- iv. Accumulated privileged leave / sick leave, which is expected to be encashed / utilized within next 12 months, is treated as short term employee benefit. The company measures the expected cost of such absences as the additional amount that it expects to pay as a result of the unused entitlement that has accumulated at the reporting date.

k) Impairment of Assets

The carrying amounts of assets are reviewed at each balance sheet date if there is any indication of impairment based on internal/external factors. An impairment loss is recognized wherever the carrying amount of an asset exceeds its recoverable amount. The recoverable amount is the greater of the assets' net selling price and value in use. In assessing, value in use, the estimated future cash flows are discounted to their present value at the weighted average cost of capital.

After impairment, depreciation/amortization is provided on the revised carrying amount of the asset over its remaining useful life.

l) Provision, Contingent Liability & Contingent Assets

The Company creates a provision when there is present obligation as a result of a past event that probably requires an outflow of resources, and a reliable estimate can be made of the amount of obligation. Provisions are determined based on best estimates of the amount required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current best estimates.

A disclosure for a contingent liability is made when there is a possible obligation or a present obligation that probably will not require an outflow of resources or where a reliable estimate of the obligation cannot be made. Contingent assets are neither recorded nor disclosed in the financial statements.

m) Taxation

Current income tax

Current income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted, at the reporting date.

Deferred tax

The deferred tax for timing differences between the book and tax profits for the year is accounted for, using the tax rates and laws that have been substantively enacted as of the reporting date.



Deferred tax charge or credit reflects the tax effects of timing differences between accounting income and taxable income for the period. The deferred tax charge or credit and the corresponding deferred tax liabilities or assets are recognized using the tax rates that have been enacted or substantively enacted by the balance sheet date. Deferred tax assets are recognized only to the extent there is reasonable certainty that the assets can be realized in future; however, where there is unabsorbed depreciation or carry forward of losses, deferred tax assets are recognized only if there is a virtual certainty of realization of such assets. Deferred tax assets are reviewed at each balance sheet date and are written down or written up to reflect the amount that is reasonably/virtually certain (as the case may be) to be realized.

At each reporting date, the Company reassesses the unrecognized deferred tax assets, if any.

n) Leases

As a Lessee:

Operating Leases

Leases, where the lessor effectively retains substantially all the risks and benefits of ownership of the leased item, are classified as operating leases. Operating lease payments are recognized as an expense in the Statement of Profit and Loss on a straight-line basis over the lease term.

o) Earnings per Share

Basic earnings per share are calculated by dividing the net profit or loss after tax for the period attributable to equity shareholders (after deducting preference dividends and attributable taxes) by the weighted average number of equity shares outstanding during the period.

The weighted average numbers of equity shares are adjusted for events such as bonus issue, bonus element in the rights issue, share split and reverse share split (consolidation of shares) that have changed the number of equity shares outstanding, without corresponding change in resources.

For the purpose of calculating diluted earnings per share, the net profit or loss for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period are adjusted for the effects of all dilutive potential equity shares.

p) Cash and Cash Equivalents

Cash and cash equivalents for the purpose of cash flow statement comprise of cash at bank and in hand and short-term investments with an original maturity of three months or less.

q) Use of Estimates

The preparation of financial statements in conformity with Indian GAAP requires management to make judgement, estimates and assumptions that affect the reported amounts of revenue, expenses, assets and liabilities and disclosure of contingent liabilities, at the end of reporting period. Actual results could differ from those estimates under different assumptions and conditions.



Suraksha Diagnostic Private Limited

Notes forming part of the Standalone Financial Statements as at and for the year ended March 31, 2022
CIN: U85110WB2005PTC102265

Estimates and underlying assumptions are reviewed at each balance sheet date. Any revision to accounting estimates is recognized in accordance with the requirements of the respective accounting standard.

- r) All amounts disclosed in the standalone financial statements and notes have been rounded off to the nearest lacs as per the requirements of Schedule III, unless otherwise stated. Any amount appearing as Rs 0.00 represents less than Rs 500.



3 Share capital

Particulars	As at March 31, 2022	As at March 31, 2021
Authorised :		
12,20,000 equity shares of Rs. 100/- each (March 31, 2021: 12,20,000 equity shares of Rs.100/- each)	1,220.00	1,220.00
1,80,000 0.0001% Compulsorily Convertible Preference Shares of Rs. 100 each (March 31, 2021: 1,80,000 0.0001% Compulsorily Convertible Preference shares of Rs. 100/- each)	180.00	180.00
Total	1,400.00	1,400.00
Issued Subscribed and Fully Paid Up Shares :		
Equity Share Capital		
6,90,000 (Previous Year: 6,90,000) Equity Shares of Rs. 100/- each	690.00	690.00
Preference Share Capital		
1,62,859 (Previous Year: 1,62,859) 0.0001% Compulsory Convertible Cumulative Preference Share of Rs.100/- each	162.86	162.86
Total	852.86	852.86

(a) (i) Reconciliation of no. of equity shares & amount outstanding at the beginning and at the end of the year

Particulars	As at March 31, 2022		As at March 31, 2021	
	No. of Shares	Amount	No. of Shares	Amount
Equity Shares outstanding at the beginning of the year	6,90,000	690.00	6,90,000	690.00
Equity Shares Outstanding at the end of the year	6,90,000	690.00	6,90,000	690.00

(ii) Reconciliation of no. of preference shares outstanding at the beginning and at the end of the year

Particulars	As at March 31, 2022		As at March 31, 2021	
	No. of Shares	Amount	No. of Shares	Amount
0.0001% Compulsorily Convertible Preference Shares outstanding at the beginning of the year	1,62,859	162.86	1,62,859	162.86
0.0001% Compulsorily Convertible Preference Shares outstanding at the end of the year	1,62,859	162.86	1,62,859	162.86

(b) (i) Rights, preferences and restrictions attached to equity shares

The Company has only one class of equity share having face value of Rs.100/- each (March 31, 2021: Rs.100/- each). Each shareholder is entitled to one vote per share held. The company declares and pays dividends in Indian rupees. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the General Meeting. The above shareholding represent the legal ownership of shares.

In the event of liquidation of the Company, the equity shareholders shall be entitled to receive remaining assets of the Company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders. Equity Shares held by OrbiMed Asia II Mauritius FDI Investments Limited in the Company carry certain protective rights under the terms of the Shareholders Agreement.

(ii) Rights, preferences and restrictions attached to 0.0001% Compulsorily Convertible Preference Shares

Each 0.0001% Compulsorily Convertible Preference Shares has a face value of Rs 100/- (March 31, 2021: Rs.100/- each) and are convertible into 1(One) Equity Share of Rs 100 each at such time as required but mandatorily convertible after 19 years. The preference shares carry a dividend of 0.0001% per annum on the face value to be paid out of profits of the Company. The preference share was issued on 27 March 2017.

(c) (i) Details of Equity Shares held by each Shareholder holding more than 5% of the Company :

Name of Shareholder	As at March 31, 2022		As at March 31, 2021	
	No. of Shares held	% of holding	No. of Shares held	% of holding
Kishan Kumar Kejriwal	76,945	11.15%	76,945	11.15%
Dr. Somnath Chatterjee	66,000	9.57%	49,976	7.24%
Ritu Mittal	1,57,769	22.87%	1,21,661	17.63%
Satish Verma	1,33,689	19.38%	1,59,275	23.08%
Tinni Investment Limited	38,512	5.58%	38,512	5.58%
OrbiMed Asia II Mauritius FDI Investments Limited	1,34,587	19.51%	1,34,587	19.51%
Total	6,07,502	88.06%	5,80,956	84.19%

(ii) Details of 0.0001% Compulsorily Convertible Preference Shares held by each Shareholder holding more than 5% of the Company :

Shareholders Name	As at 31-Mar-2022		As at 31-Mar-2021	
	No. of Shares held	% of holding	No. of Shares held	% of holding
OrbiMed Asia II Mauritius FDI Investments Limited	1,62,859	100.00%	1,62,859	100.00%
Total	1,62,859	100.00%	1,62,859	100.00%

(d) Disclosure of shareholding of promoters

Shareholders Name	As at 31-Mar-2022		As at 31-Mar-2021	
	No. of Shares held	% of holding	No. of Shares held	% of holding
Kishan Kumar Kejriwal	76,945	11.15%	76,945	11.15%
Dr. Somnath Chatterjee	66,000	9.57%	49,976	7.24%
Ritu Mittal	1,57,769	22.87%	1,21,661	17.63%
Satish Verma	1,33,689	19.38%	1,59,275	23.08%
Total	4,34,403	62.97%	4,07,857	59.10%

(e) Disclosure of % of change in shareholding of promoters

Shareholders Name	As at 31-Mar-2022		As at 31-Mar-2021	
	No. of Shares held	% of Change In Shareholding	No. of Shares held	% of Change In Shareholding
Dr. Somnath Chatterjee	66,000	2.32%	49,976	0.00%
Ritu Mittal	1,57,769	5.23%	1,21,661	7.69%
Satish Verma	1,33,689	(3.70%)	1,59,275	0.00%



4 Reserves & Surplus		
Particulars	As at March 31, 2022	As at March 31, 2021
Securities Premium Account		
Balances at beginning of the year	4,837.09	4,837.09
Add: Securities Premium credited on share issue		
Balances at end of the year	4,837.09	4,837.09
Surplus In Statement of Profit and Loss :		
Balances at beginning of the year	6,936.36	6,288.91
Add : Profit for the Year	2,375.10	647.45
Less: Dividend to Preference Share holders*	(0.00)	(0.00)
	9,311.46	6,936.36
Total	14,148.55	11,773.45

* Amount is below the rounding off norms adopted by the Company.

5 Long-Term Borrowings		
Particulars	As at March 31, 2022	As at March 31, 2021
Secured		
Term Loan for Medical Equipment's: (Refer note below)		
From Banks	1,104.52	826.65
Car Loans: (Refer note below)		
From Banks	19.24	
Car Loans:		
From a Financial Institution	15.19	26.39
	1,138.95	853.04
Unsecured		
Working Capital Term Loan:		
From Banks (Refer note below)	89.18	139.81
	89.18	139.81
Total	1,228.13	992.85

Details of rate of interest, repayment and securities with respect to term loans for Medical Equipment's

The aforesaid term loans are secured against the hypothecation over Medical Equipment's against which such loans has been taken and Personal Guarantee of Directors. Such loans are repayable in equal monthly instalment over a period varying from 36 months to 68 months along with interest in the range of 8.55% to 9.80% p.a.

Details of rate of interest, repayment and securities with respect to Car Loans

The aforesaid term loans are secured against the hypothecation over Vehicle's against which such loans has been taken and Personal Guarantee of Directors. Such loans are repayable in equal monthly instalment over a period of 36 months along with interest in the range of 8.25% to 9.75% p.a.

Details of rate of interest, repayment and securities with respect to Working Capital Term Loan

The aforesaid working capital term loan is unsecured and is repayable in equal monthly instalment over a period of 48 months along with interest of 8.25% p.a.

6 Deferred Tax Liabilities (Net) - Non-Current		
Particulars	As at March 31, 2022	As at March 31, 2021
Deferred Tax Liability		
Temporary differences in carrying cost of PPE & Intangibles assets between books of accounts & tax purpose	1,062.88	1,104.91
Gross deferred tax liability	1,062.88	1,104.91
Deferred Tax Asset		
Expenses allowable on payment, write off, etc.	47.55	118.71
Provision for Employee Benefits	10.62	3.29
Gross deferred tax asset	58.17	122.00
Net Deferred Tax Liabilities	1,004.71	982.91

7 Long-Term Provisions		
Particulars	As at March 31, 2022	As at March 31, 2021
Provision for employee benefits		
Gratuity (Refer Note 32)	1.05	
Defined Benefit - Leave	30.09	11.01
Total	31.14	11.01

* Amount is below the rounding off norms adopted by the Company.



8 Short-Term Borrowings		
Particulars	As at March 31, 2022	As at March 31, 2021
Secured - Current maturities of Long Term Borrowings (Refer Note 5)		
Term Loan for Medical Equipment's:		
From Banks	608.93	616.72
Car Loans:		
From Banks	2.69	4.06
Car Loans:		
From Financial Institution	11.56	9.53
	623.18	630.31
Unsecured - Current maturities of Long Term Borrowings (Refer Note 5)		
Working Capital Term Loan:		
From Banks	50.63	19.90
	50.63	19.90
Total	673.81	650.21

10 Other Current Liabilities		
Particulars	As at March 31, 2022	As at March 31, 2021
Security deposit received from collection centres	65.53	78.31
Capital creditors	23.20	83.73
Advance from Customers	65.87	2.45
Interest accrued but not due	7.37	4.97
Employee Benefits Payable	330.81	315.27
Statutory Dues payable	133.70	89.09
Other payables	-	9.97
Total Other current liabilities	626.48	583.79

11 Short-Term Provisions		
Particulars	As at March 31, 2022	As at March 31, 2021
Provision for Income tax (net of advance tax and tax deducted at source amounting to Rs. 1549.63 lacs (March 31 2021): Rs Nil)	114.21	-
Provision for Dividend of Preference Shares*	0.00	0.00
Provision for employee benefits		
Defined Benefits - Leave	6.39	0.30
Total	120.60	0.30

* Amount is below the rounding off norms adopted by the Company.



Suraksha Diagnostic Private Limited

CIN:U85110WB2005PTC102265

Notes forming part of the Standalone Financial Statements as at and for the year ended March 31, 2022
(all amounts in INR Lacs, unless stated otherwise)

9 Trade payables

Particulars	As at March 31, 2022	As at March 31, 2021
At amortised cost		
Total outstanding dues of micro enterprises and small enterprises	4.29	4.63
Total outstanding dues of creditors other than micro enterprises and small enterprises	1,382.98	1,255.69
Total	1,387.27	1,260.32

Based on the information available with the Company, there are no outstanding dues and payments made to any supplier of goods and services beyond the specified period under Micro, Small and Medium Enterprises Development Act, 2006 [MSMED Act]. There is no interest payable or paid to any suppliers under the said Act.

9.1 Information in terms of Section 22 of Micro, Small and Medium enterprises Development Act, 2006(MSMED) are given below:

Particulars	As at March 31, 2022	As at March 31, 2021
(i) Principal amount remaining unpaid to any supplier as at the end of the accounting year.	4.29	4.63
(ii) The amount of interest due and payable for the year (where the principal has been paid)	-	-
(iii) The amount of interest paid by the buyer in terms of section 16 of the MSMED Act 2006	-	-
(iv) The amount of interest accrued and remaining unpaid at the end of each accounting year.	-	-
(v) The amount of further interest remaining due and payable even in the succeeding years,	-	-
Interest payable to micro, small and medium enterprises	-	-

9.2 Trade Payables Ageing Schedule - Based on the requirements of Amended Schedule III

Particulars	Outstanding as on March 31, 2022 from due date of payment						Total
	Unbilled Due	Not Due	Upto 1 Year	1-2 years	2-3 years	More than 3 years	
Total outstanding dues of micro enterprises and small enterprises	-	-	4.29	-	-	-	4.29
Total outstanding dues of creditors other than micro enterprises and small enterprises	68.38	985.91	242.23	86.46	-	-	1,382.98
Disputed dues of micro enterprises and small enterprises	-	-	-	-	-	-	-
Disputed dues of creditors other than micro enterprises and small enterprises	-	-	-	-	-	-	-
Total	68.38	985.91	246.52	86.46	-	-	1,387.27

Particulars	Outstanding as on March 31, 2021 from due date of payment						Total
	Unbilled Due	Not Due	Upto 1 Year	1-2 years	2-3 years	More than 3 years	
Total outstanding dues of micro enterprises and small enterprises	-	-	4.63	-	-	-	4.63
Total outstanding dues of creditors other than micro enterprises and small enterprises	68.18	756.90	178.83	251.78	-	-	1,255.69
Disputed dues of micro enterprises and small enterprises	-	-	-	-	-	-	-
Disputed dues of creditors other than micro enterprises and small enterprises	-	-	-	-	-	-	-
Total	68.18	756.90	183.46	251.78	-	-	1,260.32



12 Property, Plant & Equipment And Capital Work in Progress

Particulars	Property, Plant and Equipment										Total	Capital Work in Progress	
	Land- Freehold (Refer Note 12.3 below)	Buildings (Refer Note 12.3 below)	Plant & Machinery	Computer Hardware	Furniture and Fixtures	Laboratory Equipment (Refer Note 12.3 below)	Vehicles	Computer Server	Office Equipment				
Gross Block													
As at March 31, 2020	79.26	974.67	977.35	637.67	3,800.12	11,787.57	368.53	60.32	328.01	19,013.50	38.24	0.86	
Additions	-	13.67	24.00	13.67	186.33	669.41	-	-	16.89	910.30	-	-	
Disposals	-	-	-	-	525.11	98.52	4.06	-	9.67	637.36	-	-	
Transfer	-	-	-	-	38.24	-	-	-	-	38.24	(38.24)	-	
As at March 31, 2021	79.26	974.67	1,001.35	651.34	3,499.58	12,358.46	364.47	60.32	335.23	19,324.68	0.86	-	
Additions	10.40	-	97.60	53.11	194.36	634.21	42.12	-	30.10	1,061.90	737.39	-	
Disposals	-	-	6.27	-	340.24	133.88	29.80	-	-	376.31	-	-	
Transfer	-	-	19.25	27.12	446.98	-	-	-	1.70	628.94	(628.94)	-	
As at March 31, 2022	79.26	985.07	1,111.93	731.57	4,140.92	12,786.31	376.79	60.32	367.03	20,639.21	109.31	-	
Accumulated Depreciation													
As at March 31, 2020	-	17.26	491.94	541.28	1,371.07	3,739.28	129.03	54.93	181.35	6,536.14	-	-	
Charge for the year	-	15.43	96.46	40.89	345.76	886.32	42.47	2.04	45.18	1,474.55	-	-	
Disposals	-	-	-	-	268.85	87.26	2.30	-	8.91	367.32	-	-	
As at March 31, 2021	-	32.69	588.40	582.17	1,447.98	4,538.34	169.20	56.97	217.62	7,633.37	-	-	
Charge for the year	-	15.58	88.02	43.58	377.53	885.56	41.72	0.26	48.71	1,450.96	-	-	
Disposals	-	-	4.41	-	-	174.70	21.32	-	-	200.43	-	-	
As at March 31, 2022	-	48.27	672.01	625.75	1,775.51	5,249.20	189.60	57.23	266.33	8,883.90	-	-	
Net Block													
As at March 31, 2021	79.26	941.98	412.95	69.17	2,051.60	7,820.12	195.27	3.35	117.61	11,691.31	0.86	-	
As at March 31, 2022	79.26	936.80	439.92	105.82	2,365.41	7,537.11	187.19	3.09	100.70	11,755.30	109.31	-	

12.2 Addition through Acquisitions related to cost of property, plant & equipment of two diagnostics centre's which has been acquired by the Company against a Purchase Consideration of Rs. Nil (Previous Year: Rs. 6,35.98 lacs) and details are mentioned as below :

Description of Assets	Addition through Acquisitions	
	As at March 31, 2022	As at March 31, 2021
Plant & Machinery	-	11.86
Computer Hardware	-	2.65
Furniture and Fixtures	-	82.18
Laboratory Equipment	-	531.63
Office Equipment	-	7.66
Total	-	635.99

12.2 Capital Work in Progress (CWP) ageing schedule - Based on the requirement of Amended Schedule III

Particulars	Amount in CWP for the period of			Total
	Less than 1 year	1-2 years	More than 3 years	
Projects in progress	109.31	-	-	109.31
Total	109.31	-	-	109.31

Particulars	Amount in CWP for the period of			Total
	Less than 1 year	1-2 years	More than 3	
Projects in progress	0.86	-	-	0.86
Total	0.86	-	-	0.86

12.3 The Company has created a first and exclusive charge by way of mortgage over its entire land and building along with hypothecation of certain medical equipment having a net block of Rs.1,826.16 lacs (Gross Block of Rs.3,013.19 lacs) (Previous Year: Rs Nil (Gross block of Rs Nil) against personal loan taken by its director.



Suraksha Diagnostic Private Limited

CIN:U85110WB2005PTC102265

Notes forming part of the Standalone Financial Statements as at and for the year ended March 31, 2022

(all amounts in INR Lacs, unless stated otherwise)

13 Intangible Assets

Particulars	Other Intangible Assets		Intangible assets under development
	Computer software	Total	
Gross Block			
As at March 31, 2020	433.45	433.45	-
Additions	-	-	15.05
Disposals	-	-	-
Transfer	-	-	-
As at March 31, 2021	433.45	433.45	15.05
Additions	10.57	10.57	-
Transfer	15.05	15.05	(15.05)
As at March 31, 2022	459.07	459.07	-
Accumulated Amortisation			
As at March 31, 2020	128.91	128.91	-
Charge for the year	96.61	96.61	-
Disposals	-	-	-
As at March 31, 2021	225.52	225.52	-
Charge for the year	58.17	58.17	-
Disposals	-	-	-
As at March 31, 2022	283.69	283.69	-
Net Block			
As at March 31, 2021	207.93	207.93	15.05
As at March 31, 2022	175.38	175.38	-

13.1 Intangible Assets Under Development (IAUD) Aging schedule - Based on the requirements of Amended Schedule III

As at March 31, 2022

Particulars	Amount in IAUD for a period of				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Projects in progress	-	-	-	-	-
Total	-	-	-	-	-

As at March 31, 2021

Particulars	Amount in IAUD for a period of				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Projects in progress	15.05	-	-	-	15.05
Total	15.05	-	-	-	15.05



14 Non-Current Investments		
Particulars	As at March 31, 2022	As at March 31, 2021
Long Term Investment (Trade)		
Investment in LLP's	15.50	10.50
Investment in Suraksha Speciality LLP	15.50	10.50
Total	15.50	10.50
Aggregate amount of Unquoted Investments		

(a) Details of Investment in Limited Liability Partnership			
Investment in Suraksha Speciality LLP			
Name of Partners	Share of Profit (%)	Share of Profit (%)	
Suraksha Diagnostic Private Limited	99.99%	99.99%	
Dr. Somnath Chatterjee	0.01%	0.01%	
Total Capital of LLP - Rs.15.50 lacs (Previous Year - Rs.10.50 lacs)			

15 Long-Term Loans & Advances		
Particulars	As at March 31, 2022	As at March 31, 2021
Unsecured, considered good	156.79	180.00
Prepaid Rent on Medical Equipments	40.27	-
Capital Advances		
Total	197.06	180.00

16 Other Non-Current Assets		
Particulars	As at March 31, 2022	As at March 31, 2021
Deposits with banks (Refer Note a below)	4,744.61	1,408.48
Security Deposits	740.20	700.30
Other Advances (Refer Note 33)	150.00	150.00
Advance to Gratuity Trust (Refer Note 32)	-	11.76
Total	5,634.81	2,270.54

(a) Bank deposits has been pledged by way of security for loan granted to the company or bank guarantee given, which are not encashable within next year and are renewable at the time of maturity.

17 Current Investments		
Particulars	As at March 31, 2022	As at March 31, 2021
Investment in units of Mutual Funds		
HDFC Liquid Fund, Direct Dolly, IDCW Plan - Nil (Previous Year : 53,066.33 units)	-	541.18
Total	-	541.18
Aggregate cost of Quoted Investment	-	541.21
Aggregate Net Asset Value of Quoted Investment	-	541.18

18 Inventories		
Particulars	As at March 31, 2022	As at March 31, 2021
At cost or net realisable value, whichever is lower		
Consumable Stores	622.53	444.50
Total	622.53	444.50

20 Cash & Bank Balances		
Particulars	As at March 31, 2022	As at March 31, 2021
Cash and Cash Equivalents	213.61	212.29
in Current Accounts	30.45	54.89
Cash in hand	13.96	18.40
Prepaid Bank Balances		
Other Bank Balances		
Deposits with maturity period more than three months and less than twelve months (Including accrued Interest)	25.00	149.83
Total	283.02	435.41

21 Short-Term Loans & Advances		
Particulars	As at March 31, 2022	As at March 31, 2021
Prepaid expenses	312.49	90.39
Prepaid Rent on Medical Equipments	27.86	-
Other loans and advances		
Advance to Suppliers	3.45	3.29
- Related Parties (Refer Note 34)	166.39	231.17
- Others		
Other Advances	6.82	5.10
- Related Parties	6.93	16.32
- Others		
Advance Income Tax and tax deducted and source (Net of provision of Rs. Nil (March 31, 2021 Rs. 1,110.10 lacs)		364.62
Total	523.94	710.89



19 Trade Receivables

Particulars	As at March 31, 2022	As at March 31, 2021
At amortised cost		
- Trade Receivables considered good - Secured		
- Trade Receivables considered good - Unsecured	756.70	599.53
- Trade Receivables - considered doubtful - Unsecured	163.29	407.67
	919.99	1,007.20
Less: Provision for doubtful debts	163.29	407.67
Total Trade receivables	756.70	599.53
Trade receivables include debts due by:		
Related Parties (Refer note 34)	133.63	71.18
Others	623.07	528.35
Total Trade receivables	756.70	599.53

Particulars	Outstanding from due date of payment as on March 31, 2022						Total
	Not Due	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	
Undisputed							
- considered good	226.68	307.00	194.53	19.20	9.28	-	756.70
- considered doubtful	-	-	-	124.02	39.27	-	163.29
	226.68	307.00	194.53	143.22	48.55	-	919.99
Less: Considered doubtful	-	-	-	(124.02)	(39.27)	-	(163.29)
	226.68	307.00	194.53	19.20	9.28	-	756.70
Disputed							
- considered good	-	-	-	-	-	-	-
- considered doubtful	-	-	-	-	-	-	-
Less: Considered doubtful	-	-	-	-	-	-	-
	-	-	-	-	-	-	-
Total	226.68	307.00	194.53	19.20	9.28	-	756.70

Particulars	Outstanding from due date of payment as on March 31, 2021						Total
	Not Due	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	
Undisputed							
- considered good	212.23	274.43	59.41	35.66	17.80	-	599.53
- considered doubtful	-	-	-	-	284.38	123.29	407.67
	212.23	274.43	59.41	35.66	302.18	123.29	1,007.20
Less: Considered doubtful	-	-	-	-	(284.38)	(123.29)	(407.67)
	212.23	274.43	59.41	35.66	17.80	-	599.53
Disputed							
- considered good	-	-	-	-	-	-	-
- considered doubtful	-	-	-	-	-	-	-
Less: Considered doubtful	-	-	-	-	-	-	-
	-	-	-	-	-	-	-
Total	212.23	274.43	59.41	35.66	17.80	-	599.53



Suraksha Diagnostic Private Limited

CIN:U85110WB2005PTC102265

Notes forming part of the Standalone Financial Statements as at and for the year ended March 31, 2022

(all amounts in INR Lacs, unless stated otherwise)

22 Revenue From Operations:

Particulars	For the year ended	
	31-Mar-22	31-Mar-21
Sale of services <i>Diagnostic Service Charges and related ancillary services</i>	22,319.25	13,951.12
Other Operating Revenues:		
<i>Rental Income</i>	-	27.50
<i>Income From Manpower Supply</i>	-	21.95
Total Income	22,319.25	14,000.57

23 Other Income

Particulars	For the year ended	
	31-Mar-22	31-Mar-21
<u>Interest income on</u>		
<i>Fixed Deposit</i>	163.40	55.46
<i>Income Tax Refund</i>	17.73	4.22
<i>Profit on sale of Investment</i>	0.29	29.42
<i>Dividend on Mutual Fund</i>	0.64	1.46
<i>Liabilities/Provisions no longer required, now written back</i>	37.07	33.71
<i>Miscellaneous Income</i>	11.21	13.33
Total	230.34	137.60

24 Cost of Materials Consumed

Particulars	For the year ended	
	31-Mar-22	31-Mar-21
Inventory at the beginning of the year	444.50	544.62
Add: Purchases	6,218.52	2,500.84
	6,663.02	3,045.46
Less: Inventory at the closing of the year	622.53	444.50
Total	6,040.49	2,600.96



25 Employee Benefits Expense

Particulars	For the year ended	
	31-Mar-22	31-Mar-21
Salaries, wages and bonus (Inclusive of Director's Remuneration)	3,152.56	2,294.26
Contribution to provident and other funds (Refer Note 32)	188.13	149.94
Gratuity expenses (Refer Note 32)	31.48	27.29
Staff welfare expenses	41.77	17.99
Total	3,413.94	2,489.48

26 Finance Cost

Particulars	For the year ended	
	31-Mar-22	31-Mar-21
Interest expense :		
on secured loan	130.99	149.98
on unsecured loan	21.57	6.04
Total	152.56	156.02

27 Depreciation and amortisation expense

Particulars	For the year ended	
	31-Mar-22	31-Mar-21
Depreciation on Property, Plant & Equipment (Refer note 12)	1,450.96	1,474.55
Amortisation of Intangible Assets (Refer note 13)	58.17	96.61
Total	1,509.13	1,571.16

28 Other Expenses

Particulars	For the year ended	
	31-Mar-22	31-Mar-21
Doctors Professional Fees	2,097.33	1,531.62
Sample Testing, Collection & Logistic Charges	263.35	312.25
Commission to Collection Centers	146.72	165.63
Repairs & Maintenance:		
Machinery (including medical equipment)	839.75	527.12
Others	128.63	162.28
Donation	1.35	3.54
Office Administration Expenses	479.80	410.95
Bank charges	57.81	34.30
Advertisement and sales promotion	282.19	154.16
Electricity Charges	522.30	466.69
Expense relating to Acquisition & Valuations	88.45	-
Travelling & Conveyance Charges	195.64	264.73
Telephone & Internet Charges	91.95	66.85
Insurance Charges	79.96	74.69
IT Expenses	301.47	281.08
CSR Expense (Refer Note 31)	33.72	37.39
Rent (Refer Note 35)	1,793.46	1,315.25
Rent on Medical Equipments	68.39	-
Rates & Taxes	73.31	32.17
Payment to Auditors (Refer Note 30)	14.30	12.91
Net Loss on foreign currency transactions	-	6.02
Legal & Professional Fees	169.72	122.62
Membership & subscription expenses	83.82	40.83
Freight & Other Charges	18.54	20.97
Provision for doubtful debts & advances	-	284.38
Loss on disposal of property, plant & equipment	141.48	245.03
Miscellaneous Expenses	140.66	105.77
Total	8,114.10	6,679.23



29 Earning Per Share

Particulars	For the year ended	
	31-Mar-22	31-Mar-21
Net profit after tax for the year	2,375.09	647.46
Less: Dividend to Preference Share holders*	(0.00)	(0.00)
Adjusted Net Profit after tax for the year	2,375.09	647.46
Basic Earnings per Share		
Weighted average number of ordinary shares (No. in lacs)	6.90	6.90
Nominal value of ordinary share (in Rs. Per share)	100	100
Basic earnings for ordinary shares (in Rs. per share)	344	94
Diluted earnings per share		
Weighted average number of ordinary shares	6.90	6.90
Weighted average number of ordinary shares on account of Convertible Preference Shares	1.63	1.63
	8.53	8.53
Nominal value of ordinary share (in Rs. Per share)	100	100
Diluted earnings for ordinary shares (in Rs. per share)	278	76

* Amount is below the rounding off norms adopted by the Company.

30 Payment to Auditors

Particulars	For the year ended	
	31-Mar-22	31-Mar-21
As Statutory Auditors :		
Audit Fees	12.50	11.00
Tax Audit Fees	-	-
Reimbursement of Expenses	-	-
In Other Capacity:		
Other Services	1.80	1.91
Total	14.30	12.91

31 Corporate Social Responsibility

Particulars	For the year ended	
	31-Mar-22	31-Mar-21
a) Gross amount to be spent by the Company during the year	61.09	37.54
b) Amount spent during the period		10.00
(i) Construction/ acquisition of any asset	61.10	-
(ii) On purpose other than (i) above	-	-
c) Amount unspent during the period*		27.54
d) Nature of CSR activities	Socio-Economic Development, Healthcare, Education	Socio-Economic Development, Healthcare, Education

The Company has an unspent CSR liability of Rs. 27.54 lacs as at March 31, 2021 (Previous Year: Rs. Nil). The Company has recognised unspent CSR liability of Rs. 27 lacs in the balance sheet as at March 31, 2021. There is no contractual obligation on the Company for any projects for which such provision is required. The unspent amount for March 31, 2021 was subsequently spent on May 15, 2021.

Particulars	For the year ended	
	31-Mar-22	31-Mar-21
Opening Balance	27.54	-
Gross amount to be spent during the year	33.55	37.54
Actual spent	61.10	10.00
(Excess)/Short Spent	(0.01)	27.54



Suraksha Diagnostic Private Limited

CIN:U85110WB2005PTC102265

Notes forming part of the Standalone Financial Statements as at and for the year ended March 31, 2022

(all amounts in INR Lacs, unless stated otherwise)

32 Employee benefits

In accordance with the Accounting Standard-15 'Employee Benefits', the Company has calculated the various benefits provided to employees as under:

A. Defined contribution plans

During the period the Company has recognized the following amounts in the Statement of profit and loss:-

Particulars	For the year ended 31	For the year ended 31
	March 2022	March 2021
Employers Contribution to Provident fund	142.67	113.27
Employers Contribution to Employee State Insurance	45.46	36.66
	<u>188.13</u>	<u>149.93</u>

B. Defined benefit plans

Gratuity plan

The Company has a defined benefit gratuity plan. Every employee who has completed five years or more of service is entitled to Gratuity on terms as per the provisions of The Payment of Gratuity Act, 1972. The Company has taken up a Group Gratuity Scheme with Life Insurance Corporation of India (LIC), 'Suraksha Diagnostic Private Limited Employees' Gratuity Fund' to meet its obligation towards gratuity.

The following tables summarize the components of net benefit expense recognized in the statement of profit and loss and the funded status and amounts recognized in the balance sheet for the plan.

(i) Actuarial assumptions:

The principle assumptions used in determining gratuity obligations for company's plan are shown below

Particulars	For the year ended 31	For the year ended 31
	March 2022	March 2021
Discount rate (per annum)	7.30%	6.90%
Expected Rate of increase in compensation levels	5.25%	5.25%
Expected rate of return on plan assets	6.75%	6.84%
Mortality Rate	Indian Assured Lives Mortality (2012-2014)	Indian Assured Lives Mortality (2012-2014)
Retirement age	60 Years	60 Years
Average attained age	33.32 Years	34.46 Years
Withdrawal Rate (based on age %age)		
- Upto 30 years	3%	3%
- 31 to 44 years	2%	2%
- 44 years & above	1%	1%

The estimates of future salary increase considered in actuarial valuation, takes account of inflation, seniority, promotion and other relevant factors, such as supply and demand in the employment market.

(ii) Amount to be recognized in Balance Sheet:

Particulars	As at	As at
	31 March 2022	31 March 2021
Present value of defined benefit obligations	1.06	(11.74)
Net liability / (asset) arising from defined benefit obligations	<u>1.06</u>	<u>(11.74)</u>

(iii) Expenses recognized in Statement of Profits and Losses:

Particulars	For the year ended 31	For the year ended 31
	March 2022	March 2021
Current service cost	41.18	34.97
Interest cost	17.30	17.01
Expected return on plan assets	(17.96)	(20.46)
Net actuarial loss/(gain) recognized during the year	(9.05)	(4.22)
Total charge to Statement of Profits and Losses	<u>31.47</u>	<u>27.30</u>



Suraksha Diagnostic Private Limited

CIN:U85110WB2005PTC102265

Notes forming part of the Standalone Financial Statements as at and for the year ended March 31, 2022

(all amounts in INR Lacs, unless stated otherwise)

(iv) Changes in the present value of the defined benefit obligation in respect of Gratuity are as follows:

Particulars	As at	As at
	31 March 2022	31 March 2021
Present value obligation as at the beginning of the year	250.76	246.47
Interest cost	17.30	17.01
Current service cost	41.18	34.97
Benefits paid	(30.39)	(36.50)
Actuarial loss/(gain) on obligations	(14.17)	(11.19)
Present value obligation as at the end of the year	<u>264.68</u>	<u>250.76</u>

(v) Changes in the fair value of plan assets:

Particulars	As at	As at
	31 March 2022	31 March 2021
Balance at the beginning of the year	262.50	281.47
Expected Return on plan assets	17.96	20.46
Actuarial loss/(gain) on plan assets	(5.12)	(6.97)
Actual Company Contributions	18.67	4.04
Benefits paid	(30.39)	(36.50)
Balance at the end of the year	<u>263.62</u>	<u>262.50</u>

Actual Return on Plan Assets 12.83 13.50

(vi) Net assets/liability and actuarial experience gain/(loss) for present benefit obligation ('PBO') and plan assets

Particulars	As at	As at
	31 March 2022	31 March 2021
Present value of obligation	264.68	250.75
Less: Fair Value of Plan assets	263.62	262.51
Net (assets)/liability	1.06	(11.76)
Experience (gain)/loss on PBO	(0.75)	(11.19)
Experience gain/(loss) on plan assets	(5.12)	(6.97)

(vii) Major Category of Plan Assets as a % of total Plan Assets

Funds managed by Insurer	As at	As at
	31 March 2022	31 March 2021
	100%	100%

(viii) The company has contributed Rs.44,41,754 to gratuity for next financial year.



Suraksha Diagnostic Private Limited

CIN:U85110WB2005PTC102265

Notes forming part of the Standalone Financial Statements as at and for the year ended March 31, 2022

(all amounts in INR Lacs, unless stated otherwise)

33 Contingencies & Commitments

(To the extent not provided for)

i. Contingent Liability

Particulars	As at 31-Mar-2022	As at 31-Mar-2021
Claims against the Company not acknowledged as debt (Refer note (a) below)	150.00	150.00
Guarantee to financial institution to the extent of security against loan taken by directors	2,842.22	-
	<u>2,992.22</u>	<u>150.00</u>

- (a) The Company had given an earnest money deposit by way bank guarantee of INR 1,50,00,000 (Previous Year - Rs 1,50,00,000/-) to Bihar State Health Society in 2014-15 which had been encashed by the other party on grounds of non-compliance of the term of agreement agreed upon between them. The company has filled writ petition before the Patna High Court which is pending disposal.

ii. Commitments

Particulars	As at 31-Mar-2022	As at 31-Mar-2021
Estimated amount of contract remaining to be executed on capital account	94.10	-
Less: Capital Advance	40.27	-
Total	<u>53.83</u>	<u>-</u>



Suraksha Diagnostic Private Limited

CIN:U85110WB2005PTC102265

Notes forming part of the Standalone Financial Statements as at and for the year ended March 31, 2022

(all amounts in INR Lacs, unless stated otherwise)

34 Related party Disclosures

In accordance with the requirement of Accounting Standard (AS)- 18 on "Related Party Disclosures" the names of the related parties where control exists /able to exercise significant influence along with the aggregate transactions/year end balances with them as identified and certified by the management are given below:

(A) List of Related parties :

Name of Related Party	Description of relationship
Suraksha Speciality LLP	Subsidiary of the Company
Suraksha Salvia LLP	Subsidiary of Suraksha Speciality LLP
Dr Somnath Chatterjee (Director)	Key Managerial Person (KMP)
Ritu Mittal (Director)	Key Managerial Person (KMP)
Suraksha Diagnostic & Eye Centre Private Limited	Enterprises owned or significantly influenced by KMP
Oscar Enclave Private Limited	Enterprises owned or significantly influenced by KMP
Tinni Investments Limited	Enterprises owned or significantly influenced by KMP
R.A. Enterprises	Enterprises owned or significantly influenced by KMP
Kejriwal Constructions	Enterprises owned or significantly influenced by KMP
Sahayata Clinic LLP	Enterprises owned or significantly influenced by KMP
Pragati Kejriwal	Relative of KMP
Raghavi Mittal	Relative of KMP

(B) Details of transactions with Related Parties

Particulars	For the period ended	
	March 31, 2022	March 31, 2021
Rental Income of CT Scan Machine		27.50
Suraksha Diagnostic & Eye Centre Private Limited	-	27.50
Total		
Income From Manpower Supply		21.95
Suraksha Diagnostic & Eye Centre Private Limited	-	21.95
Total		
Sale of Services	244.10	-
Suraksha Diagnostic & Eye Centre Private Limited	244.10	-
Total		
Purchase of Consumables		958.04
R.A. Enterprise	1,536.06	958.04
Total	1,536.06	958.04
Rent Expense		336.92
Oscar Enclave Private Limited	444.79	45.70
Kejriwal Constructions	62.19	29.43
Suresh Enterprise	31.15	
Total	538.13	412.05
Professional Fees to relative of KMP		4.950
Pragati Kejriwal	6.000	-
Raghavi Mittal	0.900	
Total	6.900	4.950
Commission Paid		-
Sahayata Clinic LLP	0.17	
Total	0.17	
Loan repaid (including interest)		1.05
Tinni Investment Limited	-	1.05
Total		
Investment made in LLP		0.50
Suraksha Speciality LLP	5.00	0.50
Total	5.00	0.50



Suraksha Diagnostic Private Limited

CIN:U85110WB2005PTC102265

Notes forming part of the Standalone Financial Statements as at and for the year ended March 31, 2022

(all amounts in INR Lacs, unless stated otherwise)

(C) Receivable from & Payable to Related Parties are set out below:

Particulars	As at March 31, 2022	As at March 31, 2021
Receivable from:		
Suraksha Diagnostic & Eye Centre Private Limited (Trade Receivable)	125.38	71.18
Suraksha Salvia LLP (Other Advances)	6.82	5.10
Oscar Enclave Private Limited (Security Deposit)	114.60	114.60
Suraksha Diagnostic & Eye Centre Private Limited (Advances from Suppliers)	3.44	3.29
Sahayata Clinic LLP (Advances from Suppliers)	0.01	-
Ritu Mittal (Other Receivable)	5.50	-
Somnath Chatterjee (Other Receivable)	2.75	-
Total	258.50	194.16
Payable for:		
R.A. Enterprise (Trade Payable)	238.59	255.56
Oscar Enclave Pvt Ltd (Trade Payable)	33.92	31.71
Kejriwal Constructions (Trade Payable)	4.74	4.41
Suresh Enterprise (Trade Payable)	2.38	2.43
Ritu Mittal	7.88	8.12
Somnath Chatterjee	7.88	8.12
Total	295.39	310.35

(D) Remuneration of Key Management Personnel

The remuneration of key management personnel and a relative of key management personnel of the Company are set out below in aggregate for each of the categories specified in AS 18 'Related party disclosures'.

Particulars	For the period ended	
	31 March 2022	31 March 2021
Salary & Allowance		
Dr. Somnath Chatterjee	144.00	92.26
Ritu Mittal	144.00	92.26
Guarantee Fee		
Dr. Somnath Chatterjee	2.75	-
Ritu Mittal	5.50	-
Total Director's Remuneration	296.25	184.52



35 Leases

Operating lease: Group as lessee

The Company's significant leasing arrangements are in respect of operating leases for -

- a. Premises (office, diagnostic centre's etc.) - These leasing arrangements are cancellable in nature as per the terms of individual agreement and are usually renewable on mutual consent basis. The aggregate lease rentals payable are charged as 'Rent' under Note 28.

- b. Medical Equipment – The Company has entered into leasing agreement for certain medical equipments with a vendor. These non cancellable leases are for a period of 7 years. The aggregate lease rentals payable are charged as 'Rent on medical equipment' under Note 28 (inclusive of variable rental expense of Rs. 58.04 lacs (March 31 2021 – Rs Nil)

Future minimum rentals payments under non-cancellable operating leases are as follows:

	31 March 2022	31 March 2021
Within one year	27.86	-
After one year but not more than five years	111.43	-
More than five years	45.35	-
Total	184.64	-

36 Segment Reporting

(A) Information about primary segments

The primary segment of the Company is business segment which comprises of carrying on the business of diagnostic centers for providing various pathology and radiology services. The entire operations are governed by the same set of risks and returns and hence is considered as representing a single business segment.
As the Company operates in a single primary business segment, no separate segment information has been disclosed.

(B) Segment information for secondary segment reporting (by geographical segment)

The company's entire revenue comes from customers located in India, therefore no separate geographical segment has been presented.



37 Ratio Analysis and Its Elements

Ratios	March 31, 2022		March 31, 2021		Ratio as on		Variation	Reason (If variation is more than 25%)
	Numerator	Denominator	Numerator	Denominator	March 31, 2022	March 31, 2021		
Current Ratio	2,186.19	2,808.16	2,731.51	2,494.62	0.78	1.09	(28.44%)	There has been decrease in current ratio due to increase in working capital due operational requirement during COVID period
Debt-Equity Ratio	1,901.94	15,001.41	1,643.06	12,626.31	12.68%	13.01%	0.00%	Increase in Debt Service Coverage Ratio is majorly due to increase in Earnings before interest, depreciation and taxes in the current year
Debt Service Coverage ratio	4,981.06	108.71	2,368.50	321.06	4581.96%	737.72%	520.87%	Increase in Return on Equity ratio is majorly due to increase in Profit after taxes in the current year
Return on Equity ratio	2,375.10	15,001.41	647.45	12,626.31	15.83%	5.13%	220.00%	Increase in revenue from operations operations in the current year has improved the in inventory turnover ratio
Inventory Turnover ratio	6,040.49	533.52	2,600.96	494.56	11.32	5.26	115.21%	Increase in revenue from operations for the year is by 59.42% whereas increase in trade receivables is by 24.84% which indicates the company's collection of accounts receivable as efficient, thus increasing the trade receivable turnover ratio
Trade Receivable Turnover Ratio	22,319.25	678.12	14,000.57	599.52	32.91	23.35	40.94%	Increase in credit purchase during the year has impacted the trade payable turnover ratio
Trade Payable Turnover Ratio	6,218.52	1,323.79	2,500.84	639.69	4.70	3.91	20.20%	Increase in revenue from operations has increased the Net Capital Turnover Ratio
Net Capital Turnover Ratio	22,319.25	15,001.41	14,000.57	12,626.31	1.49	1.11	34.23%	Increase in Net Profit ratio is majorly due to increase in increase in revenue from operations which has increased Profit after taxes by more than 250% in the current year
Net Profit ratio	2,375.10	22,319.25	647.45	14,000.57	10.64%	4.62%	120.00%	Increase on revenue from operations has increased the profit before tax which significantly increased the return on capital employed for the current financial year
Return on Capital Employed	3,471.93	16,903.34	797.34	14,269.37	20.54%	5.59%	250.00%	The reduction on return of investemnet is due to shift of investments from mutual fund to fixed deposit
Return on Investment	164.33	4,785.11	86.33	2,109.99	3.43%	4.09%	(25.00%)	



Suraksha Diagnostic Private Limited

CIN:U85110WB2005PTC102265

Notes forming part of the Standalone Financial Statements as at and for the year ended March 31, 2022

(all amounts in Rs. unless stated otherwise)

38 Additional regulator information required by Schedule III

a. Title deeds of Immovable Properties not held in name of the Company

The company does not own any immovable property

b. The Company has not revalued its property, plant and equipment or intangible assets during the current or previous year.

c. No Loans or Advances in the nature of loans are granted to promoters, directors, KMPs and the related parties (as defined under Companies Act, 2013), either severally or jointly with any other person.

d. The Company does not have any Benami property and there are no proceedings have been initiated or pending against the company for holding any Benami property.

e. The company has not borrowed any fund from banks or financial institution on the basis of security of current assets and hence there is no requirement of filing quarterly returns or statements of current assets with banks or financial institutions.

f. The Company has not been declared wilful defaulter by any banks or financial institution or government or any government authority.

g. The Company has no transactions with the companies struck off under Companies Act, 2013 or Companies Act, 1956

h. The Company does not have any charges or satisfaction which is yet to be registered with ROC beyond the statutory period.

i. The company has complied with the number of layers prescribed under clause (87) of section 2 of the Act read with the Companies (Restriction on number of Layers) Rules, 2017.

j. The Company has not entered into any scheme of arrangement which has an accounting impact on current or previous financial year.

k. Utilisation of Borrowed funds and share premium

(i) The Company has not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the Intermediary shall:

(a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or

(b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries

(ii) The Company has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:

(a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or

(b) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries

l. There is no income surrendered or disclosed as income during the current or previous year in the tax assessments under the Income Tax Act, 1961, that has not been recorded in the books of account.

m. The Company has not traded or invested in Crypto currency or Virtual Currency during the current and previous year.



Suraksha Diagnostic Private Limited

CIN:U85110WB2005PTC102265

Notes forming part of the Standalone Financial Statements as at and for the year ended March 31, 2022

(all amounts in Rs. unless stated otherwise)

39 Disclosures pursuant to section 186 of the Companies Act 2013:

Guarantee given to the extent of security to Kotak Mahindra Investments Limited against loan taken by Somnath Chaterjee and Ritu Mittal (Directors)

31 March 2022 31 March 2021

2842.22

(The Company has given guarantee to the extent of security provided to Kotak Mahindra Investments Ltd. against personal loan taken by Directors of the Company for Rs. 6,700 lacs (Previous Year: Rs Nil). The Company has created a first and exclusive charge by way of mortgage over its entire land and building along with hypothecation of certain medical equipment owned by the Company amounting to Rs 1,826 lacs (Previous Year: Rs Nil))

40

The Code on Social Security 2020 ('the Code') relating to employee benefits, during the employment and post-employment, has received Presidential assent on September 28, 2020. The Code has been published in the Gazette of India. Further, the Ministry of Labour and Employment has released draft rules for the Code on November 13, 2020. However, the effective date from which the changes are applicable is yet to be notified and rules for quantifying the financial impact are also not yet issued. The Company will assess the impact of the Code and will give appropriate impact in the financial statements in the period in which, the Code becomes effective and the related rules to determine the financial impact are published.

41 COVID Note


The management has made an assessment of impact of Covid-19 on the Company's operations, financial performance and position as at and for the year ended March 31, 2022 and has concluded that there is no impact which is required to be recognised in the standalone financial statements. Accordingly, no adjustments have been made to the standalone financial statements.

42 Previous year figures

Previous year's figures have been regrouped/rearranged wherever considered necessary.


As per our report of even date
For M S K A & Associates
Chartered Accountants

ICAI Firm Registration No.: 105047W


Puneet Agarwal
Partner
Membership No: 064824



For and on behalf of the Board of Directors of
Suraksha Diagnostic Private Limited


Dr Somnath Chaterjee
Director


Ritu Mittal
Director

Place: Kolkata
Date: 30-09-2022

